At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLTX MoonLake Immunotherapeutics
Post-Mkt 06-29 19:55:07 EDT
19.91
+0.01
+0.05%
盘后19.94
+0.03+0.17%
18:28 EDT
High20.14Low19.70Vol1.31M
Open20.07D1 Closing19.90Amplitude2.21%
Mkt Cap1.64BTradable Cap973.26MTotal Shares82.62M
T/O26.24MT/O Rate2.69%Tradable Shares48.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MoonLake Immunotherapeutics Announces $200 Million Public Offering
TIPRANKS  ·  06-25
MoonLake Immunotherapeutics Announces $200 Million Public Offering
Moonlake Immunotherapeutics Slides After $200 Mln Share Sale
Reuters  ·  06-24
Moonlake Immunotherapeutics Slides After $200 Mln Share Sale
H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  06-24
H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)
BRIEF-Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share
Reuters  ·  06-24
BRIEF-Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share
MoonLake Immunotherapeutics prices upsized public offering at USD 200 million
Reuters  ·  06-24
MoonLake Immunotherapeutics prices upsized public offering at USD 200 million
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
THOMSON REUTERS  ·  06-24
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
MoonLake: Prices Offering of 9 Mln Class a Shares at $20 per Share
THOMSON REUTERS  ·  06-24
MoonLake: Prices Offering of 9 Mln Class a Shares at $20 per Share
MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60
Reuters  ·  06-24
MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
TIPRANKS  ·  06-23
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
MoonLake Immunotherapeutics Shares Fall About 4% to $21.28 After the Bell Following Public Offering Announcement
THOMSON REUTERS  ·  06-23
MoonLake Immunotherapeutics Shares Fall About 4% to $21.28 After the Bell Following Public Offering Announcement
MoonLake Immunotherapeutics plans USD 150 million follow-on share offering
Reuters  ·  06-23
MoonLake Immunotherapeutics plans USD 150 million follow-on share offering
MoonLake Immunotherapeutics - Announces Proposed $150 Mln Public Offering of Class a Shares and Pre-Funded Warrants
THOMSON REUTERS  ·  06-23
MoonLake Immunotherapeutics - Announces Proposed $150 Mln Public Offering of Class a Shares and Pre-Funded Warrants
MoonLake Immunotherapeutics - Proceeds to Fund Sonelokimab Activities and General Corporate Purposes
THOMSON REUTERS  ·  06-23
MoonLake Immunotherapeutics - Proceeds to Fund Sonelokimab Activities and General Corporate Purposes
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
TIPRANKS  ·  06-23
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)
TIPRANKS  ·  06-23
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)
MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment
Dow Jones  ·  06-22
MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
TIPRANKS  ·  06-22
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
MoonLake says Phase 3 VELA trials show sonelokimab hits 67% HiSCR75 at Week 52 in hidradenitis suppurativa
Reuters  ·  06-22
MoonLake says Phase 3 VELA trials show sonelokimab hits 67% HiSCR75 at Week 52 in hidradenitis suppurativa
MoonLake Announces Week 52 Results of Sonelokimab From Its Phase 3 Vela Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
THOMSON REUTERS  ·  06-22
MoonLake Announces Week 52 Results of Sonelokimab From Its Phase 3 Vela Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares
Reuters  ·  06-19
MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares

Introduction

Company Name.
MoonLake Immunotherapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.
Issue price:
--